CLINICAL TRIAL DETAIL
FV-100 vs. Valacyclovir in Patients with Herpes Zoster
The purpose of this study is to determine if a new experimental drug (the study drug) is as good or better than another available drug, Valacyclovir, for the treatment of Herpes Zoster (Shingles). The study drug is called FV-100. We want to know how safe and how well the study drug works compared to Valacyclovir. Two doses of the study drug will be used in this research study along with one dose of Valacyclovir.
| Contact Information: | Maureen G. Keene, 503-228-7350 |
| Medical Condition(s): | Herpes Zoster (Shingles) |
| Doctor/Investigator: | Jon Hanifin |
| Age Group: | Adult |
| Eligibility Criteria: | Adult male or female subjects at least 50 years or older, experiencing Herpes Zoster (Shingles) rash for no more than 3 days, with Herpes Zoster (Shingles) related pain. |
| Chance of Placebo: | N/A |
| Compensation: | $30.00 per completed study visit for a maximum total of $330.00 if all study visits are completed. |
| Duration: | 90 days |
| Recruitment End: | June 30, 2010 |
| Sponsor(s): | Inhibitex, Inc. |
| IRB#: | IRB00005361 |
No comments:
Post a Comment